Silexion Therapeutics Corp SLXN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.23
- Day Range
- $0.21–0.23
- 52-Week Range
- $0.21–40.70
- Bid/Ask
- $0.21 / $0.22
- Shares Outstanding
- 14.47M
- Market Cap
- $1.19M
- Volume/Avg
- 821,086 / 10M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 13
- Website
- https://silexion.com
Valuation
|
Metric
|
SLXN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.75 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SLXN
Financial Strength
|
Metric
|
SLXN
|
|---|---|
Quick Ratio | 0.56 |
Current Ratio | 0.94 |
Interest Coverage | −1,084.54 |
Quick Ratio
SLXN
Profitability
|
Metric
|
SLXN
|
|---|---|
Return on Assets (Normalized) | −199.26% |
Return on Equity (Normalized) | −664.67% |
Return on Invested Capital (Normalized) | −333.56% |
Return on Assets
SLXN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?@W$kT | LOCK|>P$# | $129B | |||
| Moderna Inc
MRNA
| LOCK|&f@>^q | LOCK|t# | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|s<Pf&X | LOCK|RdbcC | $77B | |||
| argenx SE ADR
ARGX
| LOCK|JSZ?$% | LOCK|fPW | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?GZmsNx | LOCK|hM! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>$!F<Db | LOCK|t#$QL | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|S@sQz$K& | LOCK|CSPXP | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|tqZ$>< | LOCK|>vP | $24B | |||
| Incyte Corp
INCY
| LOCK|?x>%T>Y | LOCK|Vh | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!fr@%# | LOCK|h$ | $14B |
United States